Buprenorphine-naloxone microdosing

Autor: Jacqueline Myers, Radhika Marwah, Zack Dumont, Caitlin Coons
Rok vydání: 2020
Předmět:
Zdroj: Can Fam Physician
ISSN: 1715-5258
0008-350X
Popis: Objective To raise awareness of alternative techniques that can facilitate buprenorphine-naloxone treatment for opioid use disorder. Sources of information PubMed was searched for articles using the terms buprenorphine, buprenorphine/naloxone, micro-dosing, opioid agonist therapy, and induction. Other relevant guidelines, presentations, and resources were consulted. Main message Buprenorphine-naloxone is the first-line option for opioid agonist therapy owing to its superior safety profile compared with methadone. The uptake of this potentially life-saving drug has been limited by unfamiliarity and prescribing restrictions, but perhaps the biggest barrier is the prerequisite that patients be in moderate to severe withdrawal before initiation. An induction option that does not require withdrawal or immediate cessation of current opioid use, termed microdosing, is an appealing choice for patients and a practical approach that can be used by a broader array of practitioners, ultimately increasing access to buprenorphine-naloxone. Family physicians play an important role in the current opioid crisis by helping patients transition to opioid agonist therapy. Conclusion Microdosing is a safe and easy-to-implement regimen that can be used in a variety of practice settings with the help of community pharmacists. This article provides an overview of microdosing and serves as a guide to starting and maintaining treatment.
Databáze: OpenAIRE
Externí odkaz: